lifestyle.celebhomes.net
Home
Sample Page
Author:
Kyverna Therapeutics, Inc.
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Breaker Session at AAN Annual Meeting
April 21, 2026
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 9, 2026
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 3, 2026